- The shares have fallen off lately, but this happens on a news-driven stock.
- It’s an attractive risk/reward play but the underlying story warrants patience but we still think that will pay off.
- MRTP status is the obvious catalyst to come, with FDA regulation of nicotine levels further out.
- Its quest for MRTP status is significantly enhanced by the FDA plans to mandate nicotine levels and will open up lots of commercial opportunities.
SHU Portfolio: An Update On 22nd Century Group
May 10th, 2018 · No Comments